82_FR_13507 82 FR 13460 - Government-Owned Inventions; Availability for Licensing

82 FR 13460 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 47 (March 13, 2017)

Page Range13460-13460
FR Document2017-04834

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 82 Issue 47 (Monday, March 13, 2017) 
[Federal Register Volume 82, Number 47 (Monday, March 13, 2017)]
[Notices]
[Page 13460]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-04834]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

N6, A Novel, Broad, Highly Potent HIV-Specific Antibody

Description of Technology

    The N6 antibody has evolved a unique mode of binding that depends 
less on a variable area of the HIV envelope known as the V5 region and 
focuses more on conserved regions, which change relatively little among 
HIV strains. This allows N6 to tolerate changes in the HIV envelope, 
including the attachment of sugars in the V5 region, a major mechanism 
by which HIV develops resistance to other VRC01-class antibodies. N6 
was shown in pre-clinical studies to neutralize approximately 98 
percent of HIV isolates tested. The studies also demonstrate that N6 
neutralizes approximately 80 percent of HIV isolates which were 
resistant to other antibodies of the same class, and does so very 
potently. Its breadth and potency makes N6 a highly desirable candidate 
for development in therapeutic or prophylactic strategies.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

     HIV therapeutic
     HIV prophylactic

Competitive Advantages

     Neutralized 98 percent of HIV isolates tested.
     Neutralized 80 percent of HIV isolates which were 
resistant to other antibodies of the same class, and does so very 
potently.
    Development Stage: Pre-Clinical.
    Inventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, 
Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng, all of NIAID.
    Publications: Huang, Jinghe, et al. ``Identification of a CD4-
binding-site antibody to HIV that evolved near-pan neutralization 
breadth.'' Immunity 45.5 (2016): 1108-1121.
    Intellectual Property: HHS Reference No. E-131-2015 et seq.--US 
provisional application 62/136,228, US provisional application 62/
250,378, and PCT application PCT/US2016/023145.
    Licensing Contact: Chris Kornak, 240-627-3705, 
[email protected].
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is seeking parties interested in 
collaborative research to further co-develop this technology. For 
collaboration opportunities, please contact Chris Kornak, 240-627-3705, 
[email protected].

    Dated: March 3, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-04834 Filed 3-10-17; 8:45 am]
 BILLING CODE 4140-01-P

13460 Federal Register / Vol. 82, No. 47 / Monday, March 13, 2017 / Notices Agenda: To review and evaluate grant commercialization of results of Inventors: Mark Connors, Jinghe applications. federally-funded research and Huang, Byong Ha Kang, John Mascola, Place: National Institutes of Health, 6701 development. Foreign patent Elise Ishida, Tongqing Zhou, Peter Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). applications are filed on selected Kwong, Anqi Zheng, all of NIAID. Contact Person: Mary Custer, Ph.D., inventions to extend market coverage Publications: Huang, Jinghe, et al. Scientific Review Officer, Center for for companies and may also be available ‘‘Identification of a CD4-binding-site Scientific Review, National Institutes of for licensing. antibody to HIV that evolved near-pan Health, 6701 Rockledge Drive, Room 4148, FOR FURTHER INFORMATION CONTACT: neutralization breadth.’’ Immunity 45.5 MSC 7850, Bethesda, MD 20892, (301) 435– Licensing information and copies of the (2016): 1108–1121. 1164, custerm@csr.nih.gov. patent applications listed below may be Intellectual Property: HHS Reference Name of Committee: Center for Scientific obtained by communicating with the Review Special Emphasis Panel; PAR Panel: No. E–131–2015 et seq.—US provisional Neural Regulation of Cancer. indicated licensing contact at the application 62/136,228, US provisional Date: March 29, 2017. Technology Transfer and Intellectual application 62/250,378, and PCT Time: 12:00 p.m. to 4:30 p.m. Property Office, National Institute of application PCT/US2016/023145. Agenda: To review and evaluate grant Allergy and Infectious Diseases, 5601 Licensing Contact: Chris Kornak, 240– applications. Fishers Lane, Rockville, MD 20852; tel. 627–3705, chris.kornak@nih.gov. Place: National Institutes of Health, 6701 301–496–2644. A signed Confidential Rockledge Drive, Bethesda, MD 20892 Disclosure Agreement will be required Collaborative Research Opportunity: (Virtual Meeting). to receive copies of unpublished patent The Technology Transfer and Contact Person: Rolf Jakobi, Ph.D., Intellectual Property Office (TTIPO) is Scientific Review Officer, Center for applications. seeking parties interested in Scientific Review, National Institutes of SUPPLEMENTARY INFORMATION: collaborative research to further co- Health, 6701 Rockledge Drive, Room 6187, Technology description follows. develop this technology. For MSC 7806, Bethesda, MD 20892, 301–495– 1718, jakobir@mail.nih.gov. N6, A Novel, Broad, Highly Potent HIV- collaboration opportunities, please Specific Antibody contact Chris Kornak, 240–627–3705, Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 16– chris.kornak@nih.gov. Description of Technology 218: Provocative Questions in Pediatric Dated: March 3, 2017. Cancer. The N6 antibody has evolved a Suzanne Frisbie, Date: April 4, 2017. unique mode of binding that depends Deputy Director, Technology Transfer and Time: 10:00 a.m. to 5:00 p.m. less on a variable area of the HIV Agenda: To review and evaluate grant Intellectual Property Office, National Institute envelope known as the V5 region and of Allergy and Infectious Diseases. applications. focuses more on conserved regions, Place: National Institutes of Health, 6701 [FR Doc. 2017–04834 Filed 3–10–17; 8:45 am] which change relatively little among Rockledge Drive, Bethesda, MD 20892 BILLING CODE 4140–01–P (Virtual Meeting). HIV strains. This allows N6 to tolerate Contact Person: Charles Morrow, MD, changes in the HIV envelope, including Ph.D., Scientific Review Officer, Center for the attachment of sugars in the V5 DEPARTMENT OF HEALTH AND Scientific Review, National Institutes of region, a major mechanism by which HUMAN SERVICES Health, 6701 Rockledge Drive, Room 6202, HIV develops resistance to other VRC01- MSC 7804, Bethesda, MD 20892, 301–451– class antibodies. N6 was shown in pre- National Institutes of Health 4467, morrowcs@csr.nih.gov. clinical studies to neutralize (Catalogue of Federal Domestic Assistance approximately 98 percent of HIV National Institute of Allergy and Program Nos. 93.306, Comparative Medicine; isolates tested. The studies also Infectious Diseases; Notice of Closed 93.333, Clinical Research, 93.306, 93.333, demonstrate that N6 neutralizes Meeting 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National approximately 80 percent of HIV isolates which were resistant to other Pursuant to section 10(d) of the Institutes of Health, HHS) antibodies of the same class, and does Federal Advisory Committee Act, as Dated: March 7, 2017. amended (5 U.S.C. App.), notice is so very potently. Its breadth and Natasha M. Copeland, potency makes N6 a highly desirable hereby given of the following meeting. Program Analyst, Office of Federal Advisory candidate for development in The meeting will be closed to the Committee Policy. therapeutic or prophylactic strategies. public in accordance with the [FR Doc. 2017–04807 Filed 3–10–17; 8:45 am] This technology is available for provisions set forth in sections BILLING CODE 4140–01–P licensing for commercial development 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., in accordance with 35 U.S.C. 209 and 37 as amended. The grant applications and CFR part 404, as well as for further the discussions could disclose DEPARTMENT OF HEALTH AND development and evaluation under a confidential trade secrets or commercial HUMAN SERVICES research collaboration. property such as patentable material, and personal information concerning National Institutes of Health Potential Commercial Applications individuals associated with the grant • HIV therapeutic applications, the disclosure of which Government-Owned Inventions; • HIV prophylactic would constitute a clearly unwarranted Availability for Licensing Competitive Advantages invasion of personal privacy. mstockstill on DSK3G9T082PROD with NOTICES AGENCY: National Institutes of Health, • Neutralized 98 percent of HIV Name of Committee: National Institute of HHS. Allergy and Infectious Diseases Special ACTION: Notice. isolates tested. Emphasis Panel NIAID; Investigator Initiated • Neutralized 80 percent of HIV Program Project Applications (P01). SUMMARY: The invention listed below is isolates which were resistant to other Date: March 29, 2017. owned by an agency of the U.S. antibodies of the same class, and does Time: 11:00 a.m. to 3:30 p.m. Government and is available for so very potently. Agenda: To review and evaluate grant licensing to achieve expeditious Development Stage: Pre-Clinical. applications. VerDate Sep<11>2014 17:49 Mar 10, 2017 Jkt 241001 PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 E:\FR\FM\13MRN1.SGM 13MRN1


Document Created: 2018-02-01 14:57:58
Document Modified: 2018-02-01 14:57:58
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation82 FR 13460 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR